A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity.
Sang Hee ParkXue HanFrancis LoboSakina NanjiMitsuhiro TakenoPublished in: ClinicoEconomics and outcomes research : CEOR (2020)
While the pharmacy cost was higher for abatacept compared to adalimumab, due to its higher clinical efficacy, the CPR was consistently lower for seropositive RA patients treated with abatacept. The results may be useful for healthcare decision-makers in understanding how to optimize treatment for seropositive RA patients while minimizing costs in today's budget-constrained health environment.
Keyphrases
- rheumatoid arthritis
- healthcare
- disease activity
- end stage renal disease
- interstitial lung disease
- ankylosing spondylitis
- cardiac arrest
- chronic kidney disease
- public health
- ejection fraction
- newly diagnosed
- rheumatoid arthritis patients
- peritoneal dialysis
- mental health
- prognostic factors
- cardiopulmonary resuscitation
- risk assessment
- patient reported outcomes
- social media
- replacement therapy
- human health